Yingze Wang

Dr. Yingze Wang

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
XLXingjie Liang
Xingjie Liang
HMHuan Meng
Huan Meng
YWYingze Wang
Yingze Wang
HHHaiyong He
Haiyong He
JMJie Meng
Jie Meng
LJLee Jia
Lee Jia
Cisplatin is a chemotherapeutic drug commonly used in clinics. However, acquired resistance confines its application in chemotherapeutics. To overcome the acquired resistance to cisplatin, it is reasoned, based on our previous findings of mediation of cellular responses by [Gd@C82(OH)22]nnanoparticles, that [Gd@C82(OH)22]nmay reverse tumor resistance to cisplatin by reactivating the impaired endocytosis of cisplatin-resistant human prostate cancer (CP-r) cells. Here we report that exposure of the CP-r PC-3-luc cells to cisplatin in the presence of nontoxic [Gd@C82(OH)22]nnot only decreased the number of surviving CP-r cells but also inhibited growth of the CP-r tumors in athymic nude mice as measured by both optical and MRI. Labeling the CP-r PC-3 cells with transferrin, an endocytotic marker, demonstrated that pretreatment of the CP-r PC-3-luc cells with [Gd@C82(OH)22]nenhanced intracellular accumulation of cisplatin and formation of cisplatin-DNA adducts by restoring the defective endocytosis of the CP-r cancer cells. The results suggest that [Gd@C82(OH)22]nnanoparticles overcome tumor resistance to cisplatin by increasing its intracellular accumulation through the mechanism of restoring defective endocytosis. The technology can be extended to other challenges related to multidrug resistance often found in cancer treatments.

8 February 2013 in Nanomedicine
Verified
Journal Article
Closed access
JMJie Meng
Jie Meng
JXJianmin Xing
Jianmin Xing
XMXiaowei Ma
Xiaowei Ma
WCWeipeng Cao
Weipeng Cao
JLJuan Lu
Juan Lu
YZYuliang Zhao
Yuliang Zhao
Aims: [Gd@C82(OH)22]n is a new type of nanoparticle with potent antineoplastic activity and low toxicity compared with traditional drugs. In this study, we explored, for the first time, the effect of [Gd@C82(OH)22]n on the cell cycle using human breast cancer MCF-7 and human umbilical vein endothelial ECV304 cell lines by flow cytometry. Methods: Cell viability was assessed through CCK-8 assay, and MCF-7 tumor-bearing mice were examined after 2 weeks of treatment with [Gd@C82(OH)22]n. Cell cycle-related gene expression was detected by microarray and confirmed by real-time PCR and RNAi. Results: Cell viability studies confirmed that [Gd@C82(OH)22]n inhibits breast cancer effectively with very low toxicity. Flow cytometric data and microarray results reveal that [Gd@C82(OH)22]n mediates G0/G1 arrest in both cell lines by regulating the expression of several genes, such as cyclin D2, cyclin E and CDK4, among others, in the related cell cycle. Conclusion: Results further demonstrated that [Gd@C82(OH)22]n coul...

1 January 2017 in Cancer Biology & Medicine
Verified
Journal Article
Open access
PDF file
WYWen Yan
Wen Yan
YWYingze Wang
Yingze Wang
LXLiu Xiaoli
Liu Xiaoli
Wei ZhangWei Zhang
Wei Zhang
XXXiong Xinhe
Xiong Xinhe
XLXingjie Liang
Xingjie Liang
Camptothecin-based nanodrug delivery systems

1 July 2010 in Current Drug Metabolism
Verified
Journal Article
Closed access
PDF file
YWYingze Wang
Yingze Wang
JLJuan Lv
Juan Lv
XMXiaowei Ma
Xiaowei Ma
DWDongliang Wang
Dongliang Wang
HMHuili Ma
Huili Ma
XLXingjie Liang
Xingjie Liang
Cisplatin is one of the commonly-used chemotherapeutic drugs to efficiently treat malignant tumors in clinic, however, the adverse effects of cisplatin such as nephrotoxicity, neurotoxcity, and hemolytic uremic syndrome are often observed at its clinical doses (~60 mg/m2), which limit its broader application. In earlier studies, little attention was paid to the subtle changes in the architecture of lymphatic organs after low doses of cisplatin treatment. This paper reviews current understanding of cisplatin-induced erythrocyte injury, and presents our latest finding that a low dose of cisplatin (3.6 mg/m2/day, 14 days) could induce specific hemosiderin deposition in spleen of both normal and hepatoma-22 (H22) inoculated Balb/C mice. This dose of cisplatin significantly inhibited H22-induced acute ascites development. No significant toxicity was induced by this dose of cisplatin to tissues except for hemosiderin accumulation in the spleen of both normal and H22 tumor-bearing mice. Increased splenic iron content and erythrocyte injury were observed after treatment with the low dose of cisplatin. The mRNA levels of ferroportin (FPN1) and ferritin were upregulated by 25 and 5-fold in spleen, respectively. Overexpression of FPN1 and ferritin protein were also been observed at protein levels by Western blotting analysis. In addition, the mRNA expression of hepcidin was also increased, suggesting blockage of iron recycling through FPN1 in spleen with cisplatin treatment. In conclusion, cisplatin treatment damages the erythrocytes which accumulate in the red pulp of spleen with defective recycling of FPN1 and ferritin protein. Hepcidin inhibits the function of FPN1 as iron-exporter leading to iron overloaded inside ferritins of splenic cells, which are stained with abnormal hemosiderin accumulation. These results demonstrate that cisplatin-caused hemosiderin deposition in spleen provides a valuable clue for understanding the molecular basis of toxicity of cisplatin and hemosiderin accumulation and iron metabolism in vivo.

30 May 2022 in Oncology Letters
Verified
Journal Article
Open access
PDF file
WSWeiye Shi
Weiye Shi
XYXu Yao
Xu Yao
YFYu Fu
Yu Fu
YWYingze Wang
Yingze Wang
Interferon (IFN)‑α is a cytokine that exhibits a wide range of biological activities and is used in various cancer treatments. It regulates numerous genes that serve roles in antiviral, antiproliferative and proapoptotic activities. For decades, one of the main aspects of clinical oncology has been the development of anticancer therapeutics that promote the effective elimination of cancer cells via apoptosis. However, the updated available information concerning IFN‑α‑induced cancer cell apoptosis needs to be assembled, so as to provide an improved theoretical reference for the basic scientific research and clinical treatment of malignant tumors. Therefore, the present review focuses on the potential effects of IFN‑α in inducing cancer cell apoptosis. The biological characteristics of IFN‑α, the apoptotic signaling pathways and molecular mechanisms of apoptosis caused by IFN‑α are discussed in different types of cancer cells. The present review provided a comprehensive understanding of the effects of IFN‑α on cancer cell apoptosis, which will aid in developing more efficient strategies to effectively control the progression of certain cancers.

16 February 2018 in Oncology Letters
Verified
Journal Article
Open access
PDF file
YFYu Fu
Yu Fu
YWYingze Wang
Yingze Wang
Serine/arginine-rich (SR) proteins are a family of important splicing factors, which are involved in multiple aspects of RNA processing, including splicing, mRNA nuclear export, mRNA stability and translation. Previous studies have identified a number of SR proteins that exhibit abnormal expression in various tumor types. In the present study, the expression and function of serine/arginine‑rich splicing factor 7 (SRSF7) were investigated in colon and lung cancer. Using tissue immunohistochemistry, it was observed that SRSF7 was overexpressed in colon and lung cancer tissues. As the role of SRSF7 in cancer remains to be fully elucidated, the expression of SRSF7 was knocked down in the present study by transfecting SRSF7‑specific small interfering RNAs (siRNAs) into the HCT116 colon cancer cell line and A549 lung cancer cell line, which exhibited elevated expression of SRSF7. MTS assays, western blot analysis, flow cytometry and spectrofluorometer analyses were performed to assess the effects of SRSF7 knockdown on the proliferation and apoptosis of cells. The results demonstrated that the expression of SRSF7 was efficiently knocked down by SRSF7 siRNA, and that SRSF7 knockdown inhibited proliferation and enhanced apoptosis of HCT116 and A549 cells. Further experiments involving BEAS‑2B cells stably overexpressing SRSF7, and A549 cells with stable knockdown of SRSF7 revealed that SRSF7 regulated the splicing of the apoptosis regulator Fas. Collectively, these data indicated that SRSF7 is critical for the survival of colon and lung cancer cells, and may be a potential therapeutic target for the treatment of colon and lung cancer.